Table 1.
Clinicopathological features of the patients enrolled in this study that underwent six cycles of paclitaxel/carboplatin-based chemotherapy for treatment of EOC
| Patient no. | Histology | FIGO stage | Age, y | Tumor grade* |
|---|---|---|---|---|
| 1 |
Serous |
III C |
69 |
High |
| 2 |
Serous |
III C |
57 |
High |
| 3 |
Serous |
III B |
41 |
High |
| 4 |
Serous |
II A |
50 |
High |
| 5 |
Serous |
III C |
67 |
High |
| 6 |
Serous |
III C |
64 |
High |
| 7 |
Serous |
III B |
73 |
High |
| 8 |
Adenosquamous |
II B |
51 |
High |
| 9 |
Adenosquamous |
III C |
69 |
High |
| 10 |
Serous |
III C |
55 |
High |
| 11 |
Serous |
III C |
71 |
High |
| 12 |
Serous |
III C |
60 |
High |
| 13 | Serous | III C | 53 | High |
*According to International Federation of Obstetrics and Gynecology (FIGO) criteria.